BlinkLab’s Dx 1 smartphone device shows 83.7% sensitivity and 84.7% specificity in a US pilot study for diagnosing autism and ADHD in kids, surpassing FDA thresholds. Market responded positively and share price doing nicely up around 30% since beginning of October.

https://www.tradingview.com/news/smallcaps:1a2cf3fd1094b:0-blinklab-dx-1-device-pilot-study-confirms-high-diagnostic-accuracy-and-readiness-for-fda-trial/

I remain bullish and optimistic on BB1’s potential to revolutionise mental health diagnostics and deliver strong returns.  Next the 510(k) trial with 528 children.